According to Eli Lilly’s results presentation at ESC 2024, retatrutide reduced non-HDL-C by up to 22.2% at 24 weeks and by up to 26.9% at 48 weeks, in a dose-dependent manner; apoB was reduced by up to 19.6% and 24.2% at 24 and 48 weeks, respectively. At 48 weeks, the drug reduced triglycerides and apoC-III levels by up to 40.6% and 38.0%, respectively, and it also reduced the total number of TG-rich lipoprotein particles (TRLP) regardless of their size. Reduction in large and medium TRLP was greater than in small TRLP, therefore the average size of TRLP was smaller following treatment with the drug. Retatrutide also reduced the number of total and highly atherogenic small LDL particles (LDLP), while total and small HDL particles (HDLP) were only slightly reduced. The average size of HDLP increased following treatment with the drug. At 48 weeks, the NMR-derived lipoprotein insulin resistance score was decreased by 27.4%, 31.7%, and 32.5% with the 4mg, 8mg, and 12mg dosages, respectively, following treatment.